$37.60
1.30[3.58%]
At close: May 3
$37.60
0[0.00%]
After Hours: 4:01PM EDT
Kymera Therapeutics
(NASDAQ:KYMR)Latest News for Kymera Therapeutics Stock (NASDAQ:KYMR)
Kymera Therapeutics Stock (NASDAQ: KYMR)
Categories: All
Friday, May 03, 2024
Thursday, May 02, 2024
Monday, April 22, 2024
Monday, April 08, 2024
Friday, March 01, 2024
Tuesday, February 27, 2024
Friday, February 23, 2024
Thursday, February 22, 2024
- Kymera Therapeutics Is Well-Capitalized With $745M In Cash And Runway Into The First Half Of 2027Benzinga Newsdesk - Feb 22, 2024, 7:04AM
- Kymera Therapeutics Q4 EPS $(0.25) Beats $(0.40) Estimate, Sales $47.88M Beat $41.96M EstimateBenzinga Newsdesk - Feb 22, 2024, 7:03AM
- Earnings Scheduled For February 22, 2024Benzinga Insights - Feb 22, 2024, 5:27AM
Thursday, February 15, 2024
Tuesday, January 09, 2024
- Kymera Therapeutics shares are trading higher after the company announced 2024 objectives.Benzinga Newsdesk - Jan 9, 2024, 12:05PM
- Kymera Therapeutics Outlines Key 2024 Objectives And Strategy To Progress Leading Portfolio Of Immunology And Oncology Programs, Co Well-Capitalized, With Cash In Excess Of $745M And Expected Runway Into The First Half Of 2027Benzinga Newsdesk - Jan 9, 2024, 9:19AM
Friday, January 05, 2024
Thursday, January 04, 2024
- Kymera Therapeutics Commences Public Offering Of $250M Of Shares Of Its Common Stock And, In Lieu Of Common Stock To Certain Investors, Pre-funded Warrants To Purchase SharesBenzinga Newsdesk - Jan 4, 2024, 4:02PM
- Kymera Therapeutics shares are trading higher after the company announced its immunology strategy and pipeline of its oral degraders.Benzinga Newsdesk - Jan 4, 2024, 3:28PM
- Kymera Highlights Immunology Strategy and Emerging Pipeline of Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory Diseases At The R&D DayBenzinga Newsdesk - Jan 4, 2024, 7:14AM
Wednesday, January 03, 2024
Tuesday, December 19, 2023
Monday, December 11, 2023
Thursday, December 07, 2023
Monday, November 13, 2023
- Kymera Therapeutics Announces Publication Of Phase 1 Trial Results For KT-474, A First-In-Class IRAK4 Degrader, In Nature MedicineBenzinga Newsdesk - Nov 13, 2023, 11:04AM
- Analyst Expectations for Kymera Therapeutics's FutureBenzinga Insights - Nov 13, 2023, 9:00AM
- Morgan Stanley Maintains Equal-Weight on Kymera Therapeutics, Lowers Price Target to $24Benzinga Newsdesk - Nov 13, 2023, 8:56AM
Tuesday, November 07, 2023
- Kymera Therapeutics Recent Insider ActivityBenzinga Insights - Nov 7, 2023, 10:03AM
- Chief Executive Officer at Kymera Therapeutics Exercises Options Worth $308KBenzinga Insights - Nov 7, 2023, 10:01AM
- More Than $10M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are BuyingLisa Levin - Nov 7, 2023, 6:33AM
Friday, November 03, 2023
- Piper Sandler Maintains Overweight on Kymera Therapeutics, Lowers Price Target to $38Benzinga Newsdesk - Nov 3, 2023, 5:09PM
- HC Wainwright & Co. Maintains Buy Rating for Kymera Therapeutics: Here's What You Need To KnowBenzinga Insights - Nov 3, 2023, 1:00PM
- HC Wainwright & Co. Maintains Buy on Kymera Therapeutics, Lowers Price Target to $30Benzinga Newsdesk - Nov 3, 2023, 8:05AM
Thursday, November 02, 2023
- Kymera Therapeutics To Present New Clinical Data From The Phase 1 Trial Of STAT3 Degrader KT-333 At The ASH Annual MeetingBenzinga Newsdesk - Nov 2, 2023, 9:10AM
- Kymera Therapeutics Q3 GAAP EPS $(0.90) Misses $(0.72) Estimate, Sales $4.73M Miss $15.97M EstimateBenzinga Newsdesk - Nov 2, 2023, 7:12AM
- Earnings Scheduled For November 2, 2023Benzinga Insights - Nov 2, 2023, 4:56AM
Wednesday, November 01, 2023
Friday, October 06, 2023
Monday, October 02, 2023
Friday, September 29, 2023
Thursday, September 28, 2023
Thursday, September 21, 2023
Monday, September 18, 2023
Monday, September 11, 2023
Tuesday, August 29, 2023
- The Latest Analyst Ratings for Kymera TherapeuticsBenzinga Insights - Aug 29, 2023, 10:01AM
- Verizon To Rally Around 20%? Here Are 10 Other Analyst Forecasts For TuesdayLisa Levin - Aug 29, 2023, 9:15AM
- Morgan Stanley Maintains Equal-Weight on Kymera Therapeutics, Lowers Price Target to $37Benzinga Newsdesk - Aug 29, 2023, 9:07AM